Background: Plasma B-type natriuretic peptide (BNP) level is reported to be a strong marker of congestive heart failure (CHF). Heterogeneity of the BNP levels among individuals with CHF, however, can cause confusion in interpreting the results. The influence of mitral mechanical prostheses on BNP levels in patients presenting with CHF is not well known.
-type natriuretic peptide (BNP) is mainly synthesized in the ventricular myocardium 1 and secreted in response to myocardial stretching and increased wall stress. 2 BNP is a reliable marker of congestive heart failure (CHF) that is not detected on echocardiography. The synthesis and release of BNP are increased in CHF, and the plasma level provides important therapeutic and prognostic information. 3,4 Therefore, the plasma BNP level is reported to be a strong marker of CHF. 5-7 Heterogeneity of the BNP levels among individuals with CHF, however, can cause confusion in interpretation of the results. 8 Furthermore, the plasma BNP level is also elevated in other cardiac disease states, such as aging, atrial fibrillation (AF), low body mass index (BMI), chronic obstructive pulmonary disease and renal failure (RF). 9 In contrast, BNP levels are increased in patients with mitral regurgitation. 10 In these patients the BNP levels decrease after mitral valve plasty or repair. No studies, however, have investigated how the BNP levels vary when patients develop CHF after mitral valve surgery. The influence of mitral mechanical prostheses (MMPs) on BNP levels in patients presenting with CHF is not well known. We investigated how MMPs influence BNP levels in patients with CHF.
Methods
From June 2005 to September 2006, we enrolled 226 consecutive patients with CHF admitted to Kagoshima Medical Center. The diagnosis of CHF was performed according to the Framingham criteria. At the time of the CHF diagnosis, blood samples were collected and the patients underwent echocardiography to evaluate the degrees of their CHF. All measurements were done by ultrasonographers who were unaware
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of the backgrounds of the patients and the study. The left ventricular end-diastolic volume, left ventricular end-systolic volume and left ventricular ejection fraction (LVEF) were measured and calculated using Simpson's method. The right ventricular systolic pressure (RVSP) was measured using the tricuspid regurgitant jet velocity.
Blood tests, including hemoglobin and serum creatinine and so on, were carried out. After plasma extraction from the blood samples, BNP was measured with a specific immunoradiometric assay using a commercial kit (Shionogi, Osaka, Japan).
AF was diagnosed on electrocardiography, and overt coronary artery disease was diagnosed based on a history of myocardial infarction or coronary obstructive disease on angiography.
Hypertension was defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg and/or treatment with anti-hypertensive medications. Diabetes mellitus was defined as non-fasting blood glucose >200 mg/dl and/or continuous hypoglycemic treatment. Hyperlipidemia was defined as total cholesterol ≥220 mg/dl and/or treatment with lipid-lowering drugs.
We divided the patients into 2 groups with and without MMPs (prosthesis group, n=31; native group, n=195). In the native group, 12 of the patients with valve disease had heart failure caused by mitral regurgitation. After exclusion of these 12 patients, the native group contained a final total of 183 patients. We analyzed and evaluated the plasma BNP levels and clinical performances including echocardiography to assess cardiac performance in these 2 groups. Among all the patients, 103 had systolic heart failure (SHF) with LVEF <50%. A further 111 patients had diastolic heart failure (DHF) with preserved systolic function (LVEF >50%). The estimated glomerular filtration rate (eGFR) was calculated using the new simple modification of diet in renal disease formula modified for Japanese subjects (eGFR = 0.741×175 × Age -0.203 × Cre -1.154 ). For female subjects the eGFR was further multiplied by 0.742. 11 Subjects with eGFR<60 ml · min -1 · 1.73 m -2 were defined as having RF (n=131). The remaining patients were defined as non-RF (n=83).
All patients were followed up by experienced cardiologists. The median follow-up period was 285 days. The endpoints of this study were all-cause death and rehospitalization for worsening heart failure.
Continuous variables are expressed as mean ± SD. Comparisons of continuous variables between the 2 groups were carried out using ANOVA and unpaired t-test as appropriate. Categorical variables were compared on chi-square test. The BNP levels were not normally distributed and were log-transformed before statistical analysis. Univariate and multivariate regression analysis was used to identify whether the presence of an MMP was a powerful predictor of the BNP level and to evaluate the interactions of other parameters. Kaplan -Meier curves for event-free survival were created between the 2 groups and tested for significance on log -rank test. P<0.05 was considered to indicate statistical significance.
Results
The clinical characteristics of the groups are summarized in Table 1 . The mean age and BMI were significantly lower in the prosthesis group than in the native group. Renal function and hemoglobin did not differ between the 2 groups. A history of hypertension was more prevalent in the native group than in the prosthesis group. AF was more prevalent in the native group than in the prosthesis group. Regarding medication, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers was more frequent in the native group, while use of diuretics was more frequent in the prosthesis group. Table 2 lists the etiology of CHF. The cause of CHF included various etiologies in the 2 groups. In the prosthesis group, the proportion of CHF due to valvular origin was 16%. This mechanism was the cause of patient -prosthesis mismatch after mitral valve replacement. 12 An indexed effective orifice area of these patients was ≤1.25 cm 2 /m 2 . The clinical condition of that was almost identical to mitral stenosis. No patients had CHF due to mitral regurgitation in the prosthesis group. The proportion of CHF due to arrhythmia was 32%. The proportion of CHF due to other causes, for example hypertensive heart disease or anemia, was 32%. The CHF patients with ischemic heart disease (IHD) or dilated cardiomyopathy (DCM) were in a minority. Meanwhile, valvular disease, IHD and arrhythmia were similarly prevalent as the cause of CHF in the native group. In valvular disease, the HIGASHI K et al.
proportion of mitral valve disease (mitral stenosis) was 56% (n=23), the remainder of the patients had aortic valve disease (n=18). All patients with IHD had old myocardial infarction. Regarding cardiac function (Table 3) , the LVEF did not differ between the 2 groups. There were no significant changes in the left ventricular end-diastolic volume index (LVEDVI) and left ventricular end-systolic volume index (LVESVI) between the 2 groups. The left atrial diameter (LAD) and inferior vena cava (IVC) were significantly larger in the prosthesis group than in the native group. The RVSP were almost identical in the 2 groups.
The logBNP level was significantly lower in the prosthe- Effects of interactions between the presence or absence of a prosthetic valve and renal function on the logBNP levels. Blue, native group; red, prosthesis group. DHF, diastolic heart failure; RF, renal failure; SHF, systolic heart failure. (Figure 1 ; BNP level, 167± 324 pg/ml vs 498±380 pg/ml). When the subjects were divided into SHF and DHF patients by cardiac function, there were similar tendencies in the prosthesis and native groups. The logBNP level was significantly lower for the SHF and DHF patients in the prosthesis group than in the native group. The logBNP level was significantly higher in SHF patients than in DHF patients in the native group, whereas the logBNP levels did not differ significantly between SHF and DHF patients in the prosthesis group (Figure 2A) . When the subjects were divided into RF and non-RF patients by renal function, the logBNP levels were significantly lower for the RF and non-RF patients in the prosthesis group than in the native group ( Figure 2B) . The effects of the interactions between New York Heart Association (NYHA) functional classes and MMPs on the logBNP levels are shown in Figure 3 . The logBNP level increased significantly with the severity of CHF in the native group, whereas the logBNP levels did not differ significantly among the NYHA functional classes in the prosthesis group. When we compared the subjects on etiology of CHF, the logBNP level was significantly lower for the mitral valve disease patients in the prosthesis group than in the native group (4.18±0.54 vs 5.54±1.35, P=0.0395). Likewise, the logBNP level was significantly lower for the arrhythmia patients in the prosthesis group than in the native group Tables 1-3 .
HIGASHI K et al.
Univariate analysis indicated a significant association between the presence of an MMP and the logBNP level. Furthermore, the presence of an MMP was an independent adverse predictor of an elevated logBNP level on multivariate analysis ( Table 4) .
The mean periods of hospitalization were almost identical in the 2 groups (26.0±18.3 days vs 28.5±19.7 days, P=0.205). The rates of death (3.3% vs 6.5%, P=0.329) and rehospitalization for heart failure (30.1% vs 25.8%, P=0.831) during follow up did not differ between the 2 groups. On KaplanMeier analysis there were no significant differences in time to death or rehospitalization for heart failure between the 2 groups (Figure 4) .
Discussion
The present results have shown that the BNP levels in patients with MMPs were significantly lower than in patients without MMPs when they were admitted for CHF. This finding was seen regardless of cardiac and renal function. The BNP levels in patients with MMPs were not affected by the severity of their functional symptom classes of CHF. On multivariate analysis the presence of an MMP was found to be an independent predictor for a decreased level of BNP. The mean period of hospitalization and the rates of death and rehospitalization for CHF during follow up did not differ between the 2 groups. These observations mean that the severity of CHF was similar between the 2 groups. In other words, the BNP levels in the prosthesis group underestimate the real severity of CHF.
BNP is produced in both atria and ventricles, 13 but becomes upregulated in the failing ventricular myocardium. 14 BNP is secreted by several mechanisms, most notably in response to mechanical stretch. 15 Clearance of BNP from the blood is mediated by natriuretic peptide receptor (NPR)-A. In addition, BNP is degraded by a neutral endopeptidase that opens its ring structure and inactivates the peptide. Direct renal filtration and passive excretion may also be responsible for some BNP clearance. Tsutamoto et al 16 reported that BNP levels begin to rise at an eGFR threshold of 60 ml · min -1 · 1.73 m -2 . Patients with chronic renal dysfunction may have increased levels of BNP owing to decreased renal filtration, decreased clearance by NPR-A and the endopeptidase within renal tissues, or decreased renal responsiveness to BNP. 17 In the present study there were no differences between the 2 groups regarding renal function. Therefore, we do not consider that there was increased clearance of BNP in the patients with MMPs. It is possible that production of BNP deteriorated in the patients with MMPs, even if they developed CHF.
Despite evidence that BNP is secreted in states of ventricular overload, there are significant intra-individual and inter-individual variations in both healthy subjects and those with CHF, making interpretation of BNP levels difficult. There are several notable reasons for these variations. BNP is related to both age and sex. Specifically, BNP levels increase with age and are more elevated in female than in male subjects. 18, 19 Furthermore, BNP levels are lower in obese patients than in non-obese patients. 20, 21 Although the reason for the latter relationship is unknown, an observed increase in the concentration of the NPR-C clearance receptor on adipocyte cells has led some researchers to postulate that increased clearance is the reason for the lower BNP levels in obese patients. 22 In addition to age, sex and BMI, there are other physiological reasons for the BNP variability. AF is a common comorbidity in patients with CHF and valvular heart disease. BNP is elevated in outpatients with chronic AF. 23 Analysis of cardiac venous samples has suggested the presence of increased BNP secretion from the atria in patients with AF. 24 The presence of AF must be taken into account when interpreting BNP levels. Transient myocardial ischemia is associated with an immediate rise in the circulating BNP level. 25 Ischemic burdens can cause transient left ventricular systolic and diastolic dysfunction, and the degree of myocardial ischemia is independently associated with the magnitude of the increase in the BNP level.
Although the subjects in the prosthesis group had a lower BMI and a higher prevalence of AF, their BNP level was lower than that in the native group. This finding may arise because the subjects in the prosthesis group were younger than those in the native group and had a lower prevalence of 
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hypertension. The proportion of patients taking medicines, such as angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diuretics was higher in the prosthesis group than in the native group. On multivariate analysis, however, age, hypertension and drugs were not independent predictors for a decrease in the logBNP level.
Regarding echocardiographic parameters, LVEF, LVEDVI, LVESVI, RVSP and LVMI did not differ between the 2 groups. The LAD and IVC were larger in the prosthesis group than in the native group, and such LAD and IVC enlargements reflect mitral valve disease and AF. These changes, however, elevate the BNP level and cannot explain the present phenomena. It is unclear why the BNP level was lower in the prosthesis group than in the native group. There are several possible mechanisms as follows. First, the mitral mechanical valve may limit the blood flow to the left ventricle. Although the BNP level was elevated in patients with mitral stenosis, 26 the level of BNP was lower than in patients with other valve diseases with left ventricular volume overload. It is possible that decreased preload does not elevate the left ventricular enddiastolic pressure (LVEDP). A diastolic overstretch increases BNP gene expression. Left ventricular end-diastolic wall stress (LVEDWS) has a better correlation with the BNP level. 27 A decreased LVEDP may bring about a low LVEDWS. Second, disruption of the mitral valve apparatus may reduce the LVEDWS. In the present study the patients in the prosthesis group did not retain their mitral valve apparatus. In a normal heart with a normal papillary annular continuity, shorting of the major axis produces lengthening of the minor axis, thereby causing the left ventricle to become more spherical. 28 Chordal disruption cannot lead to shortening of the major axis and may result in decreased tension for the left ventricle. Early movement of the atrioventricular ring toward the apex produced by papillary muscle contraction may increase preload in the circumferential midwall fibers. Disruption of the mitral valve apparatus may not produce left ventricular wall stress. Mitral valve replacement without chordal preservation results in a decrease in the ejection fraction. 29 Mitral valve replacement without preservation of the subvalvular apparatus is associated with high mortality and morbidity. 30 The BNP levels, however, were not elevated in the present study, even when patients with MMPs developed CHF. The decrease in endogenous BNP may contribute to the poor prognosis.
On univariate analysis LVEF and eGFR were significantly associated with the BNP level. On multivariate analysis including MMPs, however, they did not retain their associations with BNP. Although it is well known that cardiac and renal function have strong associations with BNP, the existence of an MMP disturbs the relationships between these factors and BNP. These effects are factors involved in the heterogeneity of BNP levels and may cause confusion for interpretation of BNP levels in a clinical setting.
In the present study the BNP level in patients with MMPs was lower than in patients with other diseases, even if they had CHF. We must take sufficient note of this phenomenon when we manage patients with mitral valve replacement. When such patients have CHF, it is possible that their BNP level may be unreliable as a marker for the severity of heart failure. Furthermore, the BNP level may not reflect the effects of treatment or the prognosis. Because patients with prosthetic valves have not been sufficiently evaluated in previous studies, the present study is the first to investigate patients with CHF after MMP replacement.
The present study had some limitations. First, hemodynamic data were not collected in all subjects. Measurement of LVEDP in the prosthesis group and subsequent calculation of the LVEDWS would allow us to confirm whether our hypothesis is correct. Second, the preoperative BNP levels in the prosthesis group were unknown. A total of 61% of the patients in the prosthesis group had received their MMP more than 10 years previously. At that time, BNP levels could not be measured in the usual clinical setting. Therefore, we were unable to evaluate the change in the BNP level from before the operation to the present time. Third, we did not measure proBNP-108 in the present study. Nishikimi et al showed that proBNP-108 was the major molecular form in ventricular tissue, and BNP-32 was the major molecular form in atrial tissue. 31 ProBNP-108 measurement may solve the mystery of the irrelevant BNP levels in the present study. Finally, the proportion of patients with MMPs among all the subjects was low in the present study. Further studies are therefore required. In conclusion, the BNP level was lower in the prosthesis group than in the native group regardless of the cardiac and renal functions and the severity of CHF. The BNP level cannot correctly reflect the severity of CHF in patients with MMPs. The BNP levels in these patients underestimate the real severity of CHF. Based on these findings, we should monitor these patients to ensure that any development of heart failure is not missed.
